Safety, Tolerability and Pharmacokinetic Characteristics Evaluation of GST-HG131 Tablets

PHASE1UnknownINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

August 18, 2020

Primary Completion Date

March 31, 2021

Study Completion Date

May 31, 2021

Conditions
Hepatitis B
Interventions
DRUG

GST-HG131 tablets

This trial includes single-dose studies and multiple-dose studies, The single-dose study included six dose groups of 10 mg, 30 mg, 60 mg, 100 mg, 150 mg, 200 mg, 250mg and 300 mg. Based on the results of a single dose, select 1 to 3 doses to conduct multiple dose studies.

DRUG

Placebo

This trial includes single-dose studies and multiple-dose studies, The single-dose study included six dose groups of 10 mg, 30 mg, 60 mg, 100 mg, 150 mg, 200 mg, 250mg and 300 mg. Based on the results of a single dose, select 1 to 3 doses to conduct multiple dose studies.

Trial Locations (1)

130000

RECRUITING

The first hospital of Jilin University, Changchun

All Listed Sponsors
lead

Fujian Cosunter Pharmaceutical Co. Ltd

INDUSTRY